312 related articles for article (PubMed ID: 10661768)
21. Long-term survival of uveal melanoma patients after surgery for liver metastases.
Frenkel S; Nir I; Hendler K; Lotem M; Eid A; Jurim O; Pe'er J
Br J Ophthalmol; 2009 Aug; 93(8):1042-6. PubMed ID: 19429579
[TBL] [Abstract][Full Text] [Related]
22. [Malignant melanoma--diagnosis and treatment].
Jacobsen KD; Fosså SD; Aamdal S
Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3094-7. PubMed ID: 17160112
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
24. Locoregional management of hepatic metastasis from primary uveal melanoma.
Sato T
Semin Oncol; 2010 Apr; 37(2):127-38. PubMed ID: 20494705
[TBL] [Abstract][Full Text] [Related]
25. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
26. [Malignant conjunctival melanoma. Clinical review with recommendations for diagnosis, therapy and follow-up].
Lommatzsch PK; Werschnik C
Klin Monbl Augenheilkd; 2002 Oct; 219(10):710-21. PubMed ID: 12447715
[TBL] [Abstract][Full Text] [Related]
27. [Standards, Options and Recommendations (SOR): clinical practice guidelines for diagnosis, treatment and follow-up of cutaneous melanoma. Fédération Nationale des Centres de Lutte Contre le Cancer].
Négrier S; Fervers B; Bailly C; Beckendorf V; Cupissol D; Doré JF; Dorval T; Garbay JR; Vilmer C
Bull Cancer; 2000 Feb; 87(2):173-82. PubMed ID: 10705288
[TBL] [Abstract][Full Text] [Related]
28. Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.
Baggetto LG; Gambrelle J; Dayan G; Labialle S; Barakat S; Michaud M; Grange JD; Gayet L
Cancer Treat Rev; 2005 Aug; 31(5):361-79. PubMed ID: 15994016
[TBL] [Abstract][Full Text] [Related]
29. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma.
Bedikian AY; Papadopoulos NE; Kim KB; Vardeleon A; Smith T; Lu B; Deitcher SR
Melanoma Res; 2008 Dec; 18(6):400-4. PubMed ID: 19011511
[TBL] [Abstract][Full Text] [Related]
30. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study.
Callejo SA; Antecka E; Blanco PL; Edelstein C; Burnier MN
Eye (Lond); 2007 Jun; 21(6):752-9. PubMed ID: 16575415
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathways mediating liver metastasis in patients with uveal melanoma.
Bakalian S; Marshall JC; Logan P; Faingold D; Maloney S; Di Cesare S; Martins C; Fernandes BF; Burnier MN
Clin Cancer Res; 2008 Feb; 14(4):951-6. PubMed ID: 18281525
[TBL] [Abstract][Full Text] [Related]
32. Uveal melanoma in Israel in the last two decades: characterization, treatment and prognosis.
Frenkel S; Hendler K; Pe'er J
Isr Med Assoc J; 2009 May; 11(5):280-5. PubMed ID: 19637505
[TBL] [Abstract][Full Text] [Related]
33. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.
Vuoristo MS; Vihinen P; Skyttä T; Tyynelä K; Kellokumpu-Lehtinen P
Anticancer Res; 2009 May; 29(5):1755-9. PubMed ID: 19443399
[TBL] [Abstract][Full Text] [Related]
34. Treatment of metastatic uveal melanoma: review and recommendations.
Albert DM; Niffenegger AS; Willson JK
Surv Ophthalmol; 1992; 36(6):429-38. PubMed ID: 1589858
[TBL] [Abstract][Full Text] [Related]
35. Treatment of liver metastases from uveal melanoma.
Rivoire M; Kodjikian L; Baldo S; Kaemmerlen P; Négrier S; Grange JD
Ann Surg Oncol; 2005 Jun; 12(6):422-8. PubMed ID: 15886904
[TBL] [Abstract][Full Text] [Related]
36. [Retrospective study of uveal melanoma].
Tóth J
Magy Onkol; 2005; 49(1):19-25. PubMed ID: 15902329
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of treatments for metastatic uveal melanoma.
Augsburger JJ; Corrêa ZM; Shaikh AH
Am J Ophthalmol; 2009 Jul; 148(1):119-27. PubMed ID: 19375060
[TBL] [Abstract][Full Text] [Related]
38. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
39. Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
Richtig E; Ludwig R; Kerl H; Smolle J
Br J Dermatol; 2005 Nov; 153(5):925-31. PubMed ID: 16225601
[TBL] [Abstract][Full Text] [Related]
40. Significance of gene expression analysis in uveal melanoma in comparison to standard risk factors for risk assessment of subsequent metastases.
Petrausch U; Martus P; Tönnies H; Bechrakis NE; Lenze D; Wansel S; Hummel M; Bornfeld N; Thiel E; Foerster MH; Keilholz U
Eye (Lond); 2008 Aug; 22(8):997-1007. PubMed ID: 17384575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
